Dosage Forms

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks? 

Formulating an ADC Development Solution

Editor of Pharmaceutical Technology Europe

Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.


Keeping Toxicity to a Minimum

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.

Best Practices in Handling HPAPIs

The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.

Majority of High-Containment CMO Facilities Located in 5EU and Switzerland, Notes GlobalData

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.


In Safe Hands

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

Lonza Expands HPAPI Capacity

Excipients and new processing techniques can make a real difference in the development of highly potent therapies.

Enabling Technologies Advance Poorly Soluble Highly Potent APIs

The ChargePoint Single Use Passive and ChargeBag create a single-use system for contained and sterile transfer of pharmaceutical powders between process steps or facilities.

Single-Use Containers for Sterile Transfer of Powders

Understanding the API, delivery mechanism, and excipient functionality is essential to solving drug solubility challenges.


Strategic Screening for Solubility Solutions

Bio/pharma companies facing new challenges in light of the increasing HPAPI market may benefit from outsourcing.

Highly Potent Drugs